Current and evolving therapies for hepatitis C

Détails

ID Serval
serval:BIB_968C82FC8236
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Current and evolving therapies for hepatitis C
Périodique
European Journal of Gastroenterology and Hepatology
Auteur⸱e⸱s
Moradpour  D., Blum  H. E.
ISSN
0954-691X (Print)
Statut éditorial
Publié
Date de publication
11/1999
Volume
11
Numéro
11
Pages
1199-202
Notes
Journal Article
Review --- Old month value: Nov
Résumé
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Therapeutic options for hepatitis C are limited. Standard monotherapy with interferon-alpha leads to a sustained response in only 10-20% of patients. Recent studies have shown improved sustained response rates for the combination of interferon-alpha and ribavirin. Despite these improvements, more effective therapies are needed. A variety of alternative agents are currently being evaluated in clinical trials. Recent advances in the molecular virology of hepatitis C have identified specific antiviral targets such as the viral NS3 serine protease, the RNA helicase, and the RNA-dependent RNA polymerase. In addition, gene therapeutic strategies aimed at inhibiting HCV gene expression and replication as well as immunotherapeutic concepts aimed at enhancing the cellular immune response against HCV are being explored in various experimental systems. These and other novel antiviral strategies may complement the existing therapeutic modalities in the future.
Mots-clé
Adjuvants, Immunologic/therapeutic use Antioxidants/therapeutic use Antiviral Agents/*therapeutic use Drug Therapy, Combination Enzyme Inhibitors/therapeutic use Hepacivirus/enzymology/genetics/immunology Hepatitis C/drug therapy/immunology/*therapy/virology Humans Interferon-alpha/therapeutic use Multicenter Studies Randomized Controlled Trials Ribavirin/therapeutic use Vaccines/therapeutic use
Pubmed
Web of science
Création de la notice
25/01/2008 16:05
Dernière modification de la notice
20/08/2019 14:58
Données d'usage